RT Journal Article
T1 Characterization of a Mesoporous Silica NanoparticleFormulation Loaded with Mitomycin C Lipidic Prodrug (MLP)and In Vitro Comparison with a Clinical-Stage LiposomalFormulation of MLP
A1 Manzano García, Miguel
A1 Gabizón, Alberto
A1 Vallet Regí, María Dulce Nombre
AB Nanomedicines have revolutionized the treatment of certain types of cancer, as is the case of doxil, liposomal formulation with doxorubicin encapsulated, in the treatment of certain types of ovarian cancer, AIDS-related Kaposi sarcoma, and multiple myeloma. These nanomedicines can improve the performance of conventional chemotherapeutic treatments, with fewer side effects and better efficiency against cancer. Although liposomes have been used in some formulations, different nanocarriers with better features in terms of stability and adsorption capabilities are being explored. Among the available nanoparticles in the field, mesoporous silica nanoparticles (MSNP) have attracted great attention as drug delivery platforms for the treatment of different diseases. Here, a novel formulation based on MSNP loaded with a potent antitumor prodrug that works in vitro as well as in a clinically evaluated liposomal formulation has been developed. This novel formulation shows excellent prodrug encapsulation efficiency and effective release of the anticancer drug only under certain stimuli typical of tumor environments. This behavior is of capital importance for translating this nanocarrier to the clinic in the near future.
PB MDPI
SN 1999-4923
YR 2022
FD 2022-07-17
LK https://hdl.handle.net/20.500.14352/73420
UL https://hdl.handle.net/20.500.14352/73420
LA eng
NO European Research Council (Advanced Grant VERDI; ERC-2015-AdG) grant number [694160]
NO Spanish “Ministerio de Ciencia e Innovación” through the project PID2019-106436RB-I00
DS Docta Complutense
RD 21 abr 2025